Stockscreener 앱 받기
1.23
0.00%
0.00
Metagenomi Therapeutics Inc 주식(MGX)의 최신 뉴스
Metagenomi Therapeutics, Inc. (NASDAQ:MGX) Analysts Are Cutting Their Estimates: Here's What You Need To Know - simplywall.st
These Analysts Think Metagenomi Therapeutics, Inc.'s (NASDAQ:MGX) Sales Are Under Threat - simplywall.st
Analysts’ Top Healthcare Picks: Metagenomi, Inc. (MGX), Kymera Therapeutics (KYMR) - The Globe and Mail
Metagenomi Therapeutics reports $27.5M loss in Q2 2026 - scanx.trade
Metagenomi Therapeutics (MGX) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Metagenomi Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Metagenomi Therapeutics: Q2 Earnings Snapshot - marketscreener.com
Metagenomi Therapeutics (MGX) revenue drops as losses widen but cash tops $120M - Stock Titan
Metagenomi Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results - The Manila Times
Metagenomi Therapeutics Inc expected to post a loss of 57 cents a shareEarnings Preview - TradingView
Metagenomi Therapeutics (MGX) Proxy filing Summary - Quartr
Metagenomi Therapeutics (MGX) AGM 2026 Summary - Quartr
Metagenomi Therapeutics (MGX) Q1 2026 earnings summary - Quartr
Metagenomi Therapeutics (MGX) Slides 2.7% as Stock Tests Key Support LevelTPO Profile - dars.gov.et
Did Metagenomi Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - AOL.com
Chardan Capital Initiates Metagenomi Therapeutics(MGX.US) With Buy Rating, Announces Target Price $5 - Moomoo
Chardan initiates Metagenomi stock with buy, $5 target on gene therapy potential - Investing.com
Metagenomi Therapeutics (MGX) Faces Continued Pressure Near Support LevelsSchiff Line - po-news-eg.net
Metagenomi Therapeutics (MGX) Holds Steady at $1.25 as Stock Consolidates Between Key LevelsSingle Stock ETF - dars.gov.et
Metagenomi Therapeutics (MGX) Rebounds from Support, Eyes Resistance at $1.31Price Surge Stocks - dars.gov.et
Price to sales forward of Metagenomi Therapeutics, Inc. – NASDAQ:MGX - TradingView
Enterprise value to EBIT forward of Metagenomi Therapeutics, Inc. – NASDAQ:MGX - TradingView
Price to book forward of Metagenomi Therapeutics, Inc. – NASDAQ:MGX - TradingView
Price to earnings forward of Metagenomi Therapeutics, Inc. – NASDAQ:MGX - TradingView
Metagenomi Therapeutics, Inc. Actuals & Estimates (NASDAQ:MGX) - TradingView
MGX Forecast — Price Target — Prediction for 2027 - TradingView
Metagenomi Therapeutics (MGX) Edges Lower, Testing Key Support at $1.13Sign of Strength - dars.gov.et
MGX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Metagenomi Therapeutics Inc. (MGX) Q1 2026 Earnings: Wider-Than-Expected Loss Amid Continued Pipeline InvestmentDividend Increase Stocks - dars.gov.et
Metagenomi Therapeutics (MGX) Rebounds from Support; Faces Key Resistance at $1.26WMA Signal - Bölüm Sonu Canavarı
Metagenomi Therapeutics (MGX) Edges Lower as Stock Tests Key Support ZoneBull Pennant - Město Břeclav
Metagenomi Therapeutics (MGX) director awarded 17,400 stock options at $1.23 - Stock Titan
Metagenomi Therapeutics (MGX) director awarded options on 21,000 shares - Stock Titan
Metagenomi Therapeutics (MGX) director receives 21,000-share stock option grant at $1.23 - Stock Titan
Metagenomi (NASDAQ: MGX) director receives 21,000 stock options at $1.23 strike - Stock Titan
Metagenomi CFO Pamela Wapnick sells $3,746 of company stock - Investing.com UK
Metagenomi CEO Jian Irish sells $4,854 in company stock - Investing.com UK
Metagenomi general counsel Wein sells $724 in common stock - Investing.com UK
Metagenomi CFO Pamela Wapnick sells $3,746 of company stock By Investing.com - Investing.com Australia
[Form 4] Metagenomi Therapeutics, Inc. Insider Trading Activity - Stock Titan
Tax-driven sale as Metagenomi (MGX) director Irish reports 3,737 shares sold - Stock Titan
Metagenomi Announces Board Changes and Shareholder Meeting Results - TipRanks
Metagenomi Therapeutics, Inc. Announces Resignation of Brian C. Thomas, Ph.D. as A Member of the Board, Effective as of June 9, 2026 - marketscreener.com
Brian C. Thomas resigns from Metagenomi board effective June 9, 2026 - TradingView
Metagenomi (NASDAQ: MGX) director exits as shareholders back board - Stock Titan
MGX: Directors and auditor were approved, with no stockholder questions or new nominations - TradingView
MGX: Directors elected, auditor ratified, and all proposals approved with no shareholder questions - TradingView
Law firm investigates Metagenomi officers for p... - Pluang
Metagenomi Therapeutics (MGX) Slides 2.86% as Stock Tests Key Support LevelsSweep Order Flow - newsline.com
MGX Q1 2026 Earnings: Losses Widen Beyond Expectations as Pre-Revenue Biotech Focuses on PipelineEarnings Forecast Report - thelegaladvocate.com
Metagenomi Therapeutics, Inc. to Present at the Jefferies Global Healthcare Conference - The Manila Times
Metagenomi CEO to speak at Jefferies Healthcare Conference on June 4, highlighting gene-editing advances. - pluang.com
MGXMetagenomi Therapeutics Inc Stock Price and Quote - Finviz
MGX Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Advances PipelineEPS Growth Report - The Legal Advocate
MGX Q1 2026 Earnings: Missed Expectations as Pre-Revenue Biotech Advances Gene Editing PipelineEarnings Cycle Outlook - Newser
PRN_FinancialWrapper - FinancialContent
Number of shareholders of Metagenomi Therapeutics, Inc. – NASDAQ:MGX - TradingView
Metagenomi Therapeutics (MGX) price target decreased by 10.71% to 8.50 - MSN
Metagenomi Therapeutics, Inc. (NASDAQ:MGX) Just Reported And Analysts Have Been Cutting Their Estimates - Yahoo Finance
Analysts Have Lowered Expectations For Metagenomi Therapeutics, Inc. (NASDAQ:MGX) After Its Latest Results - simplywall.st
Metagenomi Therapeutics (MGX) reports Q1 loss, misses revenue estimates - MSN
0.52%
0.07%
자본화:
|
볼륨(24시간):